2025/11/01 by Alessandra De Leo, Alessio Ugolini, Filippo Veglia · 4 citations
Immunology and Microbiology · Medicine · Neuroscience · #Immune cells in cancer #Glioma Diagnosis and Treatment #Neuroinflammation and Neurodegeneration Mechanisms
paper · pdf · doi:10.1093/jimmun/vkaf283.1385
Abstract Description Immunosuppressive macrophages restrict anti-cancer immunity in glioblastoma (GBM). Here, we studied the contribution of microglia (MGs) and monocyte-derived macrophages (MDMs) to immunosuppression and mechanisms underlying their regulatory function. MDMs outnumbered MGs at late tumor stages and suppressed T cell activity. Molecular and functional analysis identified a population of glycolytic MDM expressing GLUT1 with potent immunosuppressive activity. GBM-derived factors promoted high glycolysis, lactate, and interleukin-10 (IL-10) production in MDMs. Inhibition of glycolysis or lactate production in MDMs impaired IL-10 expression and T cell suppression. Mechanistically, intracellular lactate-driven histone lactylation promoted IL-10 expression, which was required to suppress T cell activity. GLUT1 expression on MDMs was induced downstream of tumor-derived factors that activated the PERK-ATF4 axis. PERK deletion inMDMabrogated histone lactylation, led to the accumulation of intratumoral T cells and tumor growth delay, and, in combination with immunotherapy, blocked GBM progression. Thus, PERK-driven glucose metabolism promotes MDM immunosuppressive activity via histone lactylation. Funding Sources This work was supported by The Ben & Catherine Ivy Foundation Emerging Adult Glioma Award, The National Institute of Neurological Disorders and Stroke (1R01NS131912), and the American Cancer Society Institutional Research Grant (IRG-21-145-25) Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)